0001104659-19-008632.txt : 20190214 0001104659-19-008632.hdr.sgml : 20190214 20190214143242 ACCESSION NUMBER: 0001104659-19-008632 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190214 DATE AS OF CHANGE: 20190214 GROUP MEMBERS: VERSANT AFFILIATES FUND V, L.P. GROUP MEMBERS: VERSANT OPHTHALMIC AFFILIATES FUND I, L.P. GROUP MEMBERS: VERSANT VENTURE CAPITAL V (CANADA) LP GROUP MEMBERS: VERSANT VENTURES V (CANADA), L.P. GROUP MEMBERS: VERSANT VENTURES V GP-GP (CANADA), INC. GROUP MEMBERS: VERSANT VENTURES V, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90577 FILM NUMBER: 19604685 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Versant Venture Capital V, L.P. CENTRAL INDEX KEY: 0001589097 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-233-7877 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13G 1 a19-4717_2sc13g.htm SC 13G

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No.     )

 

Crinetics Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

22663K 107

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

1.

Name of Reporting Persons
Versant Venture Capital V, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
2,969,926 shares of common stock (2)

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
2,969,926 shares of common stock (2)

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,969,926 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
12.4% (3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 


(1) This Schedule 13G is filed by Versant Venture Capital V, L.P. (“VVC V”), Versant Affiliates Fund V, L.P. (“VAF V”), Versant Ophthalmic Affiliates Fund I, L.P. (“VOA”) and Versant Venture Capital V (Canada) LP (“VVC CAN”).  Versant Ventures V, LLC (“VV V”) is the sole general partner of VVC V, VAF V and VOA.  Samuel D. Colella (“Colella”), William J. Link (“Link”), Bradley Bolzon, Ph.D (“Bolzon”)., Kirk G. Nielsen (“Nielsen”), Thomas Woiwode (“Woiwode”) and Robin L. Praeger (“Praeger”) are managing directors of VV V.  Versant Ventures V GP-GP (Canada), Inc. (“VV V CAN GP”) is the sole general partner of Versant Ventures V (Canada), L.P. (“VV V CAN”, and, together with VVC V, VV V, VAF V, VOA, VVC CAN, and VV V CAN GP, the “Reporting Persons”).  VV V CAN is the sole general partner of VVC CAN.  Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V CAN GP.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VVC V.  VV V is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VVC V.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

2


 

 

1.

Name of Reporting Persons
Versant Affiliates Fund V, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
89,336 shares of common stock (2)

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
89,336 shares of common stock (2)

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
89,336 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
0.4% (3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VAF V.  VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VAF V.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

3


 

 

1.

Name of Reporting Persons
Versant Ophthalmic Affiliates Fund I, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
98,989 shares of common stock (2)

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
98,989 shares of common stock (2)

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
98,989 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
0.4% (3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VOA.  VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VOA.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

4


 

 

1.

Name of Reporting Persons
Versant Ventures V, LLC

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

 

6.

Shared Voting Power
3,158,251 shares of common stock (2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
3,158,251 shares of common stock (2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
3,158,251 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
13.1% (3)

 

 

12.

Type of Reporting Person (See Instructions)
OO

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VVC V, VAF and VOA.  VV V is the sole general partner of VVC V, VAF and VOA and may be deemed to have voting and investment power over the securities held by VVC V, VAF and VOA. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VVC V, VAF and VOA.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

5


 

 

1.

Name of Reporting Persons
Versant Venture Capital V (Canada) LP

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Ontario, Canada

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
226,025 shares of common stock (2)

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
226,025 shares of common stock (2)

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
226,025 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
0.9% (3)

 

 

12.

Type of Reporting Person (See Instructions)
PN

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

6


 

 

1.

Name of Reporting Persons
Versant Ventures V GP-GP (Canada), Inc.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

 

6.

Shared Voting Power
226,025 shares of common stock (2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
226,025 shares of common stock (2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
226,025 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
0.9% (3)

 

 

12.

Type of Reporting Person (See Instructions)
OO

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

7


 

 

1.

Name of Reporting Persons
Versant Ventures V (Canada), L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

x(1)

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

 

6.

Shared Voting Power
226,025 shares of common stock (2)

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
226,025 shares of common stock (2)

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
226,025 shares of common stock (2)

 

 

10.

Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)  o

 

 

11.

Percent of Class Represented by Amount in Row 9
0.9% (3)

 

 

12.

Type of Reporting Person (See Instructions)
OO

 


(1) This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

8


 

Introductory Note: This Statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.001 per share (“Common Stock”), of Crinetics Pharmaceuticals, Inc. (the “Issuer”).

 

Item 1

 

(a)

Name of Issuer:
Crinetics Pharmaceuticals, Inc.

 

 

Address of Issuer’s Principal Executive Offices:
10222 Barnes Canyon Road, Bldg. #2

San Diego, CA  92121

 

Item 2

 

(a)

Name of Person(s) Filing:
Versant Venture Capital V, L.P. (“VVC V”)

Versant Affiliates Fund V, L.P. (“VAF V”)

Versant Ventures V, LLC (“VV V”)

Versant Ophthalmic Affiliates Fund I, L.P. (“VOA”)

Versant Venture Capital V (Canada) LP (“VVC CAN”)

Versant Ventures V GP-GP (Canada), Inc. (“VV V CAN GP”)

Versant Ventures V (Canada), L.P. (“VV V CAN”)

 

(b)

Address of Principal Business Office:
c/o Versant Ventures

One Sansome Street, Suite 3630

San Francisco, CA 94104

 

(c)

Citizenship:

 

 

Entities:

VVC V

-

Delaware

 

 

 

VAF V

-

Delaware

 

 

 

VV V

-

Delaware

 

 

 

VOA

-

Delaware

 

 

 

VVC CAN

-

Ontario, Canada

 

 

 

VV V CAN GP

-

Delaware

 

 

 

VV V CAN

-

Delaware

 

(d)

Title of Class of Securities:
Common Stock

 

(e)

CUSIP Number:
22663K 107

 

Item 3

Not applicable.

 

9


 

Item 4

Ownership.

The following information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2018:

 

Reporting Persons

 

Shares Held
Directly

 

Sole Voting
Power

 

Shared
Voting
Power

 

Sole
Dispositive
Power

 

Shared
Dispositive
Power

 

Beneficial
Ownership

 

Percentage
of Class (1)

 

VVC V

 

2,969,926

 

2,969,926

 

0

 

2,969,926

 

0

 

2,969,926

 

12.4

%

VAF V

 

89,336

 

89,336

 

0

 

89,336

 

0

 

89,336

 

0.4

%

VOA

 

98,989

 

98,989

 

0

 

98,989

 

0

 

98,989

 

0.4

%

VV V

 

0

 

0

 

3,158,251

 

0

 

3,158,251

 

3,158,251

 

13.1

%

VVC CAN

 

226,025

 

226,025

 

0

 

226,025

 

0

 

226,025

 

0.9

%

VV V CAN GP

 

0

 

0

 

226,025

 

0

 

226,025

 

226,025

 

0.9

%

VV V CAN

 

0

 

0

 

226,025

 

0

 

226,025

 

226,025

 

0.9

%

 


(1) This calculation is based upon 24,036,983 Common Shares outstanding as of October 31, 2018, as reported in the Issuer’s 10-Q filed with the SEC on November 13, 2018.

 

Item 5

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the Reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   o

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person.

 

See Items 2(a) and 4.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9

Notice of Dissolution of Group.

 

Not applicable.

 

 

10


 

Item 10

Certification.

 

Not applicable.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 14, 2019

 

 

 

Versant Venture Capital V, L.P.

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Affiliates Fund V, L.P.

 

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Ophthalmic Affiliates Fund I, L.P.

 

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Ventures V, LLC

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Venture Capital V (Canada) LP

 

 

 

 

By:

Versant Ventures V (Canada), L.P.

 

Its:

General Partner

 

 

 

 

By:

Versant Ventures V GP-GP (Canada), Inc.

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director

 

 

 

 

Versant Ventures V (Canada), L.P.

 

 

 

 

By:

Versant Ventures V GP-GP (Canada), Inc.

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director

 

 

 

 

Versant Ventures V GP-GP (Canada), Inc.

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director

 

 

11


 

Exhibit 1

 

Joint Filing Agreement

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Crinetics Pharmaceuticals, Inc. is filed on behalf of each of us.

 

February 14, 2019

 

 

 

Versant Venture Capital V, L.P.

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Affiliates Fund V, L.P.

 

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Ophthalmic Affiliates Fund I, L.P.

 

 

 

 

By:

Versant Ventures V, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Ventures V, LLC

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

Versant Venture Capital V (Canada) LP

 

 

 

 

By:

Versant Ventures V (Canada), L.P.

 

Its:

General Partner

 

 

 

 

By:

Versant Ventures V GP-GP (Canada), Inc.

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director

 

 

 

 

Versant Ventures V (Canada), L.P.

 

 

 

 

By:

Versant Ventures V GP-GP (Canada), Inc.

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director

 

 

 

 

Versant Ventures V GP-GP (Canada), Inc.

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Director